Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort

scientific article published on 28 August 2020

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/MEG.0000000000001831
P932PMC publication ID7590962
P698PubMed publication ID32868649

P2093author name stringKarri Utriainen
Airi Jussila
Urpo Nieminen
Taina Sipponen
Markku Heikkinen
Christian Nielsen
Taru Hallinen
Erkki Soini
Ritva Koskela
Anja Eberl
Tuire Ilus
Andras Borsi
Veikko Moilanen
Christina Wennerström
Clas-Göran Af Björkesten
Heikki Nuutinen
Ilkka Vihriälä
Inka Koskinen
Jyrki Tillonen
Kalle Hakala
Mikko Heikura
Minni R Koivunen
Riikka Nissinen
Ulla-Maija Suhonen
P2860cites workA simple index of Crohn's-disease activityQ28259898
Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseQ30054715
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseQ34255362
Vedolizumab as induction and maintenance therapy for Crohn's diseaseQ34365574
A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial designQ35207745
Treat to target: a proposed new paradigm for the management of Crohn's diseaseQ38137614
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Q38619950
Long-term Efficacy of Vedolizumab for Crohn's DiseaseQ39340730
Ustekinumab induction and maintenance therapy in refractory Crohn's diseaseQ42514321
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severityQ46770065
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohortQ48172992
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.Q48282663
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.Q53658057
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.Q55693561
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDQ80838195
Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient populationQ83463037
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's DiseaseQ89125447
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyQ90656440
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesQ91329599
Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD CohortQ91809503
Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteriaQ92300916
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's DiseaseQ92488525
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE)Q92654305
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyQ92895315
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registryQ92925396
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort StudyQ93116972
Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's diseaseQ93184539
P577publication date2020-08-28
P1433published inEuropean Journal of Gastroenterology and HepatologyQ15746143
P1476titleObjectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort

Search more.